Clinical Application and Utility of PyLARIFY (18F DCFPyL) in Prostate Cancer Videos

The Diagnostic Performance of PSMA PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss The Journal of Urology publication on the Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). Prostate cancer staging is critical in multiple steps in the disease continuum, from the initial diagnosis to the...

PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris

Details
Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render PSMA i...

CONDOR: Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer - Michael J. Morris

Details
Michael Morris, Oliver Sartor, and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer. Correct localization rate (CLR), or the positive predictive value of the PyL scan, was established as the primary endpoint and the C...

Best of ASCO 2020 Prostate Cancer - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans to speak about several prostate cancer studies making an impact on the diagnosis of prostate cancer and the treatment paradigm for this disease. They highlight 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic Lymph node dissection and the CONDOR study on the impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT in men...